Although mTOR inhibitors have been approved as first-line therapy for treating metastatic clear cell renal cell carcinoma (ccRCC), the lack of useful markers reduces their therapeutic effectiveness. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.